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Introduction
Two types of approaches may be used to evaluate the toxicity of environmental agents:
• Observational population studies may be used to investigate humans or
animals in contact with the agent of interest, either prospectively or
retrospectively.
• Experimental studies may be performed under controlled conditions on
animals, living tissues or cells. These results may be extrapolated to
human and animal populations.
Observational epidemiological studies of human and animal populations
have the advantage of investigating the effects of environmentally relevant
exposures to naturally–occurring mixtures of toxins. Health effects may
be identified in the target species of concern. These studies are difficult to
implement however, as monitoring of cyanobacteria toxin occurrence in
ambient water is essential to document exposure status, and specific associations between exposure and effect are difficult to establish in free–
living populations.
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Health studies of standard test species in controlled environments address some of the difficulties described above, but they often involve the
use of species other than those of primary interest. Laboratory studies may
not closely approximate the toxin, dose or duration of exposure relevant to
environmental conditions. The effects of mixtures of natural materials and
toxins may be difficult to reproduce during repeated experiments. The advantages and disadvantages of these two strategies reveal that each may
complement and enhance the other. Neither approach is complete in itself.
Both are essential to the understanding of the potential effects of cyanobacterial toxins on human and animal populations.
The use of laboratory animals in toxicology is based on the premise that
the data obtained during controlled exposures may be extrapolated with
some degree of confidence to other species including our own. Cyanobacterial toxins are a heterogeneous group of compounds with unrelated structures, toxic endpoints, and mechanisms of action. Cyanobacterial toxins
include hepatotoxins, renal toxins, immunotoxins, neurotoxins, skin irritants and sensitizers, although mechanisms of pathogenesis are not fully
understood. Future cyanobacterial toxicity studies must consider the following components:
1. Selection of test species. The science of toxicology is replete with
examples of highly significant inter–species variability. Differences
in susceptibility to acute toxicity (e.g. TCDD), carcinogenicity (e.g.
aflatoxin), and teratogenicity (e.g. thalidomide) are well documented.
The response of different test species to a given dose of
cyanobacterial toxin will depend onspecies–related metabolic/
toxicokinetic characteristics and differences in sensitivity to the agent
studied (toxicodynamics). The majority of studies have used the
mouse because it is the smallest rodent test species and therefore
requires the least amount of toxin. Rodents are commonly used test
animals but other animals must be studied in order to address the
occurrence of specific toxicity endpoints across species.
Determination of the “appropriate” test species will therefore depend
on the information known about the site(s) of action and metabolism
of the study agent.
Although these factors are critical to
understanding the effects of cyanobacterial toxins, there are major
gaps in our knowledge of these factors for most of the toxins. Given
these data gaps, the generally accepted testing strategy is to utilize
multiple test species and to compare the results obtained in each
species with those known to occur in the target species of concern.
2. Duration of exposure. Studies need to be conducted that approximate
environmental exposures to cyanobacterial toxins. This may involve
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multiple study designs as free–living populations may be exposed to
cyanobacterial toxins chronically at low doses, and/or may experience
episodic short–term exposures to high doses. These different
exposure scenarios may, in turn, result in different spectrums of
toxicity. For example, the data from cylindrospermopsin studies
(Hawkins et al. 1997) have shown that the acute LD50 is 2000 ug/kg,
contrasted with the 5–day LD50 of only 200 ug/kg. This suggests
that the mortality seen in the two exposure groups of animals may be
the result of different types of injury, one type being acute, and the
other cumulative. Adequate characterization of cyanobacterial–
induced toxicity should include a range of exposure scenarios.
3. Route of exposure. Oral, inhalation, and cutaneous exposures to
cyanobacterial toxins may be the most likely routes of exposure
among human and animal populations. Two episodes of human
microcystin exposure by the intravenous route have been documented
among patients undergoing dialysis (Jochimsen et al. 1998, Soares et
al. 2006). In contrast, most animal toxicology studies have reported
health effects associated with intraperitoneal (i.p.) exposure to
cyanobacterial toxins. Expense and lack of sufficient test material are
the primary reasons for most cyanobacterial toxin studies having been
performed using the i.p. exposure route. The oral route of administration has been prohibitively expensive for extended studies since
the toxins are far less toxic orally than by the i.p. route (generally by
factors of 10 or more). Future laboratory animal studies should include oral, inhalation, and cutaneous exposures to evaluate effects
that may be associated with these environmentally relevant exposure
routes.
4. Characterization of cyanobacterial toxins and effects of mixtures.
Multiple cyanobacteria genera produce the same toxin, and some
produce multiple toxins. Many cyanobacterial toxins have yet to be
identified and/or characterized. The production of cyanobacterial
toxins can be highly variable, and factors associated with toxin gene
expression are poorly understood. Cylindrospermopsis raciborskii,
for example, produces widely varying amounts of cylindrospermopsin
depending upon its geographical location and environmental
conditions. A recently described cyanobacterial toxin is β–N–
methylamino–L–alanine (BMAA).
This compound may be
associated with adverse neurological effects in humans. It is possible
that BMAA occurs in multiple species of cyanobacteria including
some that occur in fresh water (Cox et al. 2005). Microcystins may
vary temporally, spatially and chemically within a water body, and
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microcystin variants differ significantly in their potential to induce
mammalian toxicity (Sivonen and Jones 1999). Experimental
evidence also indicates that any given bloom may produce more than
one cyanobacterial toxin and the resultant toxicity may be the result
of additive and/or synergistic effects among these agents. Studies on
cyanobacterial cellular extracts containing either anatoxin–a or
cylindrospermopsin have shown that the resulting toxicity was not
directly proportional to the amount of toxin in the test material itself
(Stevens and Krieger 1991; Falconer et al. 1999). In both reports, the
authors hypothesized the existence of other, as yet unidentified toxins
that were contributing to the observed adverse effects.
Studies designed to assess the effects of purified cyanobacterial toxins
such as microcystin–LR, anatoxin–a, and cylindrospermopsin, are needed
to: characterize toxicokinetics and toxicodynamics, develop biomarkers of
exposure and effect, and study specific health effects. However, this approach is hindered by a lack of toxin standards, and the fact that the study
of individual toxins does not approximate environmentally relevant exposures. The use of cellular extracts from cyanobacterial clonal cultures addresses these limitations. Cultures can be characterized, batched and used
for multiple studies among laboratories. The use of these cultures would
allow effects research to proceed in the absence of toxin standards, and
may be more representative of the spectrum and mix of toxins to which
human and animal populations are exposed.
Cyanobacteria occurrence is generally increasing as a result of eutrophication and warming of surface waters. When human and domestic animal
populations congregate around surface water sources their waste, and nutrients such as nitrogen and phosphorous, enters the water. Local populations may depend on surface waters to provide drinking water, irrigation,
food fish, and recreation. However, as population densities increase, the
occurrence of blooms increases, thus heightening the risk of human and
animal exposure to cyanobacteria toxins. Given the potency, heterogeneity, and documented occurrence of cyanobacterial toxins in US surface waters, they will increasingly be recognized as a serious public and environmental health concern.

Charge 1
What materials do we need to perform health effects research?
Ideally, investigators need well characterized, pure cyanobacterial toxins
to perform toxicity and carcinogenicity studies. The results of studies us-
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ing pure toxins are easier to interpret, and have fewer confounding variables. However, extended toxicity studies require significant quantities of
toxin to dose sufficient numbers of animals by relevant routes of exposure
(dermal, oral, and inhalation). These studies are necessary for risk assessment and the development of guidance values.
Currently the supply of pure toxin is limited. Only two oral dosing toxicity studies using pure microcystin (Fawell et al. 1994) and cylindrospermopsin (Humpage and Falconer 2003) have been implemented to date.
However, the impact of these types of studies is significant. The Fawell
study was used by the World Health Organization (WHO) as the basis for
a Guideline Value determination for microcystins. The cylindrospermopsin study is currently under review by WHO. Despite the importance of
these types of studies, few are conducted because sufficient quantities of
purified toxin are not currently available. There are published chemical
synthesis methods for microcystins, including production of the 3–amino–
9–methoxy–2,6,8–trimethyl–10–phenyl–4,6–decadienoic acid (ADDA)
residue which has been successfully synthesized (Humphrey et al. 1996;
Candy et al.1999). However, no commercial production of pure cylindrospermopsin in bulk has been reported. Although research groups have
reported chemical methods to synthesize cylindrospermopsin (Xie et al.
2000), this method is prohibitively expensive due to the 20 steps required
for synthesis.
Few toxicology studies using pure toxins have been conducted in species other than mice. Because of the limited supply of pure toxin, mice are
preferred as an animal model because of their size. However, they may
not be the best model for every target species or system of interest. Alternatively, studies with thoroughly characterized toxic extracts of cyanobacteria have yielded valuable data for domestic animals, including a study
with growing pigs which was also used by WHO in the derivation of the
human drinking water guideline (Falconer et al. 1994).
Pure toxin isolated from live cultures of cyanobacteria is available privately and commercially in limited amounts allowing the conduct of
mechanistic studies which require less material. Some investigators have
used C. raciborskii cultures (Hawkins et al. 1997; Chiswell et al. 1999;
Shaw et al. 2000). Cylindrospermopsin has been purified from C. raciborskii cultures using high performance liquid chromatography (HPLC)
(Chiswell et al. 1999). Other investigators have conducted studies with
highly purified cylindrospermopsin isolated from a bloom of Umezakia
natans collected from Lake Mikata, Fukui, Japan (Harada et al. 1994;
Terao et al. 1994). Likewise, studies with approximately 95% pure microcystin–LR have been conducted with toxin produced from Microcystis
aeruginosa, laboratory strain 7820, and purified by HPLC (Hooser et al.
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1990). Limited quantities of characterized microcystin variants LA, LR,
RR, and YR, cylindrospermopsin and nodularin are available commercially from Sigma–Aldrich (St. Louis, MO, US) and microcystin variants
LF, LR, LW, and RR from EMD Biosciences (San Diego, CA, US). Although the production method is not disclosed, these materials are suspected to have been isolated from live cultures. Regardless of source, it is
always important to verify the identity and purity of these toxins, as investigators have reported inconsistencies in research results among different
lots of toxins.
Freeze–dried natural bloom material is more widely available in larger
quantities for research studies. Dr. Ian Falconer and his colleagues have
conducted long–term microcystin toxicity and cancer promotion studies in
mice with extracts from dried natural bloom material that was from a batch
collected at Lake Mokoan in Victoria, Australia and from Malpas Dam in
New South Wales, Australia (Falconer and Humpage 1996). Both sources
of material have been characterized and used in previous research (Falconer et al. 1988, 1994). Ten peaks exhibiting the characteristic absorbance spectrum of microcystins were detected using HPLC analysis. However, none of these peaks corresponded to microcystins for which
standards were available (microcystin–LR, –YR, and –RR). Bloom materials offer the advantage of reflecting real–world exposure scenarios.
However, these materials have to be carefully evaluated for use in studies
that may be included in risk assessments. Bloom materials may not be
completely characterized and the toxicity of the mixture may be greater
than that of the identified individual components indicating that: 1) the
mixture may contain additional unidentified toxins; 2) that there may be a
synergistic effect among bioactive components of the bloom material.
Since the lack of availability of pure cyanobacterial toxins is currently
limiting the ability to perform health effects research, this workgroup
strongly recommends the development and maintenance of bulk clonal
cyanobacteria cultures shared among laboratories to facilitate screening,
bioassay development and long–term exposure studies. Extensive chemical and bioassay characterization of the test materials is needed to ensure
appropriate interpretation of study results. Due to the hazardous nature of
these materials, clarification and standardization of the import/export regulations is needed to facilitate the use of shared cyanobacterial test materials
among laboratories (Metcalf et al. 2006).
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Charge 1: What materials do we need to perform health effects
research?

Near-term Research Priorities

• Develop and maintain bulk clonal cyanobacteria cultures that can be
shared among laboratories to facilitate screening, bioassay development
and long–term exposure studies.
Long-term Research Priorities

• Develop lower cost methods of chemical synthesis to produce sufficient
quantities of standard cyanobacterial toxins.

Charge 2
What are the health effects associated with chronic and episodic
exposures?
Risk assessments of the effects of cyanobacterial toxins on human and
animal health require information produced during studies of chronic and
episodic exposures, and are insufficient if based solely on studies of acute
exposures and lethal endpoints. However, much of our knowledge of toxicity rests upon acute exposures: poisoning of animals in the natural environment, and laboratory animal studies of lethal endpoints. Considerable
advances have been made, however, in our understanding of the sub-lethal
effects of cyanobacterial toxins, and this must become the focus of research in order to insure continued progress in the understanding of the
risks associated with cyanobacterial toxin exposures.
There are strong experimental studies that demonstrate the tumor promotion activity of microcystins and nodularin, and well–designed genotoxicity studies that show cylindrospermopsin to be a potential carcinogen
(Falconer 2005). To perform effective risk assessment it is essential to
carry out carcinogenicity studies on both groups of cyanobacterial toxins.
The present limitation to both National Toxicology Program (NTP) protocol studies is the lack of available purified toxin. It is preferable to use
highly characterized toxic extracts of cultures rather than to indefinitely
defer these essential carcinogenicity trials, as humans may be currently exposed to cylindrospermopsin via drinking and recreational water exposure.
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The highest priority work is to implement carcinogenicity trials with
cylindrospermopsin because of the structure of the toxin, preliminary evidence of carcinogenicity, and the current strength of evidence of genotoxicity in a human lymphoblastoid cell line (Humpage et al. 2000a). An in
vivo study conducted by Falconer and Humpage provided preliminary evidence of the carcinogenicity of cylindrospermopsin in mice (Falconer and
Humpage 2001).
Neurodevelopmental studies are required for all groups of cyanobacterial toxins. Currently little is known about neurodevelopmental toxicity.
Early work with chronic Microcystis extract exposure to male and female
mice throughout pregnancy showed cytotoxicity in the hippocampus of
neonatal offspring (Falconer et al. 1988). These studies are especially
relevant as there is the potential for neonates to be exposed via drinking
water in formula during a period of their rapid neurologic development.
Immunomodulation and immunosuppression after exposure to microcystins has been documented (Shen et al. 2003; Shi et al. 2004; Chen et al.
2005). Adverse effects on human leukocytes in vitro have been reported at
very low doses (Hernandez et al. 2000). The potential immunotoxic effects of microcystin in human and animal populations are uncharacterized.
To our knowledge, no studies of the potential immunotoxic effects of cylindrospermopsin have been reported.
There is no strong evidence to date for the teratogenicity of microcystin
and anatoxin–a (Chernoff et al. 2002, Rogers et al. 2005, MacPhail et al.
2005). Teratogenicity studies of cylindrospermopsin are underway. Multigenerational studies are needed for most toxins although the implementation of these will need to be deferred until sufficient toxin or characterized
clonal bloom material is available.
Charge 2: What are the health effects associated with chronic
and episodic exposures?

Near-term Research Priorities

• Conduct carcinogenicity studies with cylindrospermopsin.
• Conduct neurodevelopmental studies for all groups of cyanobacterial
toxins.
• Conduct immunotoxicology studies for all groups of cyanobacterial
toxins.
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• Conduct studies of the effects of acute, episodic and chronic exposures
at sublethal concentrations.
• Implement toxicological studies using oral, inhalation, and cutaneous
exposure routes.
Long-term Research Priorities

• Implement multigenerational studies for all groups of cyanobacterial
toxins.

Charge 3
What are the health effects associated with environmental mixtures of toxins?
In naturally occurring cyanobacterial blooms, a mixture of toxins is present. Most commonly, these are mixtures of microcystins when the bloom
is Microcystis or Planktothrix or of cylindrospermopsins when the bloom
is Cylindrospermopsis, Aphanizomenon, Raphidiopsis or Umezakia. Anatoxin–a and anatoxin–a(s) are uncommonly found occurring with microcystins or cylindrospermopsins in the environment, but when this mixture
does occur, synergistic effects are possible. Bloom toxicity therefore
represents the combined toxicities of the constituent toxin variants present,
and can best be expressed as toxicity equivalents (Falconer 2005).
Under natural circumstances eutrophic water bodies form a sequence of
toxic blooms that appear to be determined primarily by water temperature.
An observed sequence in Australia is neurotoxic Anabaena, followed by
hepatotoxic Microcystis, followed by cytotoxic Cylindrospermopsis in late
summer (Bowling 1994). Populations can then potentially be exposed to
saxitoxins, followed by successive hepatotoxins with different mechanisms
of action.
Effective risk assessment of natural toxic bloom events requires a systematic assessment of mixtures of toxins for which there is currently no
data. We have little information about the health effects of exposure to
concurrent or sequential mixtures. Monitoring of cyanobacteria toxin occurrence in environmental samples is essential to detecting and understanding potentially associated health effects of exposure to mixtures of
toxins.
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Risk assessment of populations exposed to natural blooms needs to take
into consideration a range of pathological effects generated by different
cyanobacterial toxins, in sequence and in combination. These may include
measures of hepatic, immune system, and kidney impairment (Falconer
2005). In human populations, neurological impairment can be measured
by the study of the neurodevelopment of young children and with a variety
of standard tests among adults. Cancer registries may be used to assess
potential carcinogenetic effects of cyanobacterial toxins if large populations are found to be exposed.
Charge 3: What are the health effects associated with
environmental mixtures of toxins?

Near-term Research Priorities

• Implement toxicology studies of animal models exposed to mixtures of
cyanobacterial toxins to evaluate toxin synergism.
• Implement epidemiologic studies of exposed populations to assess a
variety of cyanobacterial toxin–associated health effects.
• Perform risk assessments of populations exposed to natural blooms and
multiple cyanobacterial toxins, in sequence and in combination.

Charge 4
What research is needed to better understand the public health
effects of exposures to cyanobacteria?
A well–designed study of the health effects associated with cyanobacteria
exposure in human populations requires comprehensive exposure assessment. Currently, the United States does not routinely monitor drinking or
recreational waters for the presence of cyanobacterial toxins despite the
reported presence in these waters of potentially toxic blooms. Therefore,
the magnitude of the risk of cyanobacteria toxin exposure and associated
effects to the US population is unknown. Human exposures to cyanobacterial toxins may be broadly categorized for the purpose of public health
investigation into acute or chronic (episodic) exposures. Study methods
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and approaches will vary depending upon the size of the population and
the characteristics of exposure.
Acute exposures to cyanobacteria and their toxins may occur via the
oral, dermal, inhalational or intravenous exposure routes. The most common exposures are believed to occur during recreational and occupational
contact with cyanobacteria in lakes, rivers and marine waters (Osborne et
al. 2001; Stewart et al. 2006). Acute, chronic, and episodic exposures may
arise from drinking water (Annadotter et al. 2001; Ressom et al. 1994;
Kuiper–Goodman et al. 1999; Duy et al. 2000; Falconer 2005), dietary intake via consumption of cyanobacterial toxin–contaminated foods (Negri
and Jones 1995; Nagai et al. 1996; Codd et al. 1999; Saker and Eaglesham
1999; de Magalhães et al. 2001), and dietary supplements (Schaeffer et al.
1999; Gilroy et al. 2000; Lawrence et al. 2001; Saker et al. 2005). Acute
human exposure has been documented via contamination of dialysate in
hemodialysis clinics (Hindman et al. 1975; Carmichael et al. 2001;
Azevedo et al. 2002; Soares et al. 2006). Outcomes may range from no
apparent effect to serious morbidity or death associated with toxicosis.
Non life–threatening allergic and allergic–like reactions (rhinitis, asthma,
eczema, conjunctivitis) have been reported but are poorly quantified, as are
acute illnesses (e.g. flu–like reactions, skin rashes) in (presumably) non–
allergic individuals (Stewart et al. 2006).
Reports of acute illness have been received from workers sampling potentially toxic cyanobacteria blooms (Reich 2005). These ranged from
anaphylactic–like reactions, to dermatitis, gastroenteritis, and respiratory
irritation. However, published reports and descriptions of exposed and ill
individuals (cases) and case series are needed as the literature is sparse
(Turner et al. 1990). This information is needed to develop more specific
case definitions, to describe the spectrum of cyanobacteria–associated
health effects, and to identify potential susceptibility factors.
Chronic or episodic exposure to cyanobacterial toxins may occur when
people are exposed occupationally or by their drinking water. The principal concern is that some cyanobacterial toxins, such as the hepatotoxins,
may have carcinogenic potential. Some epidemiological investigations
have suggested that hepatocellular carcinoma (HCC) and colorectal cancer
rates were significantly higher in regions of China where consumption of
untreated pond or ditch water was common when compared to rates in
populations drinking deep well water (Ressom et al. 1994; Falconer 2005).
However, the epidemiological evidence is contradictory; a recent retrospective study failed to identify a relationship between HCC and consumption of ditch water (Yu et al. 2002). China is a high–risk area for HCC,
accounting for some 45% of worldwide mortality and HCC is associated
with other risk factors such as chronic viral hepatitis and exposure to afla-
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toxins (Ming et al. 2002; Yu and Yuan 2004; Shi et al. 2005). Therefore,
cyanobacterial toxin exposure assessment is essential to the successful design and implementation of studies to investigate the risk of cancer associated with repeated exposure to these toxins.
Because of the lack of currently identified cyanobacteria toxin–specific
health effects, we urgently need to develop specific biomarkers of exposure and effect to use in health studies. Biomarkers of exposure include
the toxin itself, metabolites of the parent compound, and DNA or protein
adducts specific to the toxin. Recently, the use of a simple colorimetric assay was proposed to screen human serum samples for the presence of microcystins (Hilborn et al. 2005). Work is in progress to identify cylindrospermopsin metabolites and possible adducts that can be used as human
biomarkers of exposure (Humpage and Falconer 2005). Biomarkers of effect include: biochemical markers such as serum concentrations of liver
transaminases, and quantification of micronuclei in leukocytes (Falconer et
al. 1983; Humpage et al. 2000a). The use of biomarkers will strengthen
the specificity of association between exposure to cyanobacterial toxins
and health endpoints. The carcinogenicity of aflatoxin is now much better
understood through the ability to measure aflatoxin B1, its metabolites and
DNA–adducts in urine (Ross et al. 1992; Qian et al. 1994); the epidemiology of cyanobacterial toxins awaits similar advances. Potential future areas for biomarker development include the use of DNA mutations and adducts as markers of genotoxicity. Targeted studies using genomic and
proteomic techniques may be useful, however are frequently difficult to interpret. Currently, these approaches are best guided by and aligned with
the results of traditional toxicologic studies.
Epidemiologic studies are needed to evaluate the effects of exposures to
cyanobacteria and their toxins on human and animal health. Population–
based observational study designs that assess cyanobacteria exposure retrospectively are probably the most cost–effective approaches to investigate
cyanobacteria bloom–associated health effects at this time. Of particular
importance are recent event–triggered investigations. Both acute and
chronic health effects may be investigated. However, assigning exposure
histories to individuals may be problematic, particularly to those individuals or populations with chronic or episodic exposures. Retrospective studies may lack the information to examine the temporal relationship between
exposure and effect, and one design, the case–control study, requires specific case definitions which are not well defined at present.
Prospective population–based observational studies have a greater ability to associate exposure and effect due to improved exposure assessment,
which is done before health effects occur. However this approach requires
large numbers of exposed persons, is expensive, and time consuming. The
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dynamic nature of cyanobacteria blooms and toxin production presents
significant challenges for exposure characterization, study planning and
implementation.
An experimental study design can provide a higher degree of the certainty of associations between exposure and effect. The principal advantage of a large, randomized, controlled exposure study is that random assignment to a study group minimizes the differences between exposure
groups that may affect the interpretation of the study results. However, the
specific details of any proposed randomized exposure trial would need to
be closely reviewed for its scientific merits and for the protection of human subjects. Within human ethical guidelines, an experimental design
could, in theory, be applied to the study of certain acute, low risk exposures to cyanobacteria. However, randomized, controlled exposure studies
are expensive and labor intensive, and therefore are not recommended as a
research priority at this time. Resources should instead be directed to the
implementation of well–designed observational studies to investigate the
effects of human exposures to ambient concentrations of cyanobacteria and
their toxins.
Charge 4: What research is needed to better understand the
public health effects of exposures to cyanobacteria?

Near-term Research Priorities

• Develop specific biomarkers of exposure and effect.
• Implement retrospective population–based observational studies.
• Systematically collect descriptions of exposed and ill individuals (cases)
and case series.
Long-term Research Priorities

• Implement prospective population–based observational studies in those
communities with recurrent exposure events.
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Charge 5
What are the determinants of host susceptibility?
Human beings are a diverse lot, varying in age, sex, genetics, nutrition, exposure history and health status. Accurate prediction of the human health
risks of cyanobacterial toxins must be based on recognition that each one
of these variables, either alone or in combination, could affect an individual’s susceptibility to the effects of these toxins. However, little information is available at this time regarding the importance of these (and other)
factors in determining host susceptibility. This lack of knowledge is due
primarily to the sporadic nature of poisoning episodes in humans and in
other animals (i.e. wildlife, livestock, domestic animals), and the absence
of a centralized mechanism for collecting and summarizing data from
these types of events. Laboratory studies have focused largely on toxicity
produced by acute exposures in relatively homogenous laboratory test species, such as mice. Some useful data exists on the effects of cyanobacterial
toxins in some domestic animals (Falconer 2005). However, there is far
less data on the effects of toxins following sublethal acute, episodic or
chronic exposures. As a result, attempts to predict the human health risks
of cyanobacterial toxins are riddled with uncertainty.
Despite the paucity of data, it seems likely that several factors could influence the severity of outcome in humans following exposure to cyanobacterial toxins. For example, liver failure would likely be more common
following exposure to hepatotoxins in people with prior hepatic disease or
insufficiency, and irritation caused by exposure to air–borne toxins may be
greater in people with underlying respiratory disease.
Studies on laboratory animals are potentially more informative in identifying host susceptibility factors. The most common practice, referred to as
the mouse bioassay, acutely exposes mice by the i.p. route to samples suspected to contain cyanobacterial toxins (Sullivan 1993). This approach has
been widely used to determine the safety of seafood samples, as well as to
gauge potency during the extraction and purification of toxins from environmental samples. A premium has therefore been placed on standardized
conditions of testing among samples (Fernandez and Cembella 1995). As
a consequence, the potential importance of most susceptibility factors that
may be prevalent in the human population is unknown.
Two episodes of human poisonings have focused attention on age as a
potential risk factor for adverse health effects. For example, a large scale
outbreak of toxicoses among renal dialysis patients in Brazil found that
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mortality was significantly higher among older (47 vs. 35 year old) patients (Jochimsen et al. 1998). However, these patients were ill, and exposed to cyanobacterial toxins by the intravenous route; this finding may
not be applicable to people in general. Another large–scale poisoning episode involved exposure to Cylindrospermopsis via drinking water in Australia (Hawkins et. al 1985; Falconer 2005). This outbreak of hepato–
enteritis affected considerably more children that adults. However, in contrast to children, very few adults in the community drank from the local
water supply. Therefore, the higher rate of intoxication observed among
children in the population may have been due to exposure rather than to
age–related susceptibility. The role of human genetic susceptibility to effects associated with cyanobacterial toxins is unknown.
Some laboratory animal data indicate that age at exposure may influence
susceptibility to cyanobacterial toxins. For example, the acute LD50 in rats
of an extract prepared from Alaskan butter clams containing paralytic
shellfish poisoning (PSP) toxins increased with age; it is has been surmised
that the principal toxin in this extract was saxitoxin (WHO 1984). Compared to newborn rats, adult rats were about 10 times less sensitive following oral exposure, and about 2 times less sensitive following i.p. exposure
to the extract (Watts et al. 1966). Regardless of age, however, LD50 values
were considerably lower for the i.p. than the oral route of dosing (Wiberg
and Stephenson 1960). On the other hand, in mice receiving a reported i.p.
LD50 of purified microcystin LR, the time to death decreased substantially
with age (from 6 to 36 weeks). A similar age–related decrease in time to
death was also reported following an oral LD50 exposure of mice to a microcystin–containing extract (Rao et al. 2005). Recent studies found no
developmental or long–term effects in mice following repeated prenatal
exposure to sublethal doses of microcystin LR, or anatoxin–a (Chernoff et
al. 2002; Rogers et al. 2005; MacPhail and Jarema 2005). These latter
studies highlight the importance of systematic investigations into the effects of sublethal exposures involving acute, episodic and chronic exposures, in order to make accurate estimations of the health hazards associated with cyanobacterial toxins.
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Charge 5: What are the determinants of host susceptibility?

Near-term Research Priorities

• Systematically examine and report susceptibility among multiple test
species of animals exposed to cyanobacterial toxins in toxicology
studies.
• Collect and report information about susceptibility during case reports
and observational studies of humans and animals exposed to
cyanobacterial toxins.
• Implement studies of the effects of sublethal acute, episodic and chronic
exposures in healthy animals and in animal models of susceptibility.

Charge 6
What are the research needs after exposure/intoxication has occurred?
Little is known about the potential for human health effects that may persist or develop after intoxication with cyanobacterial toxins, although long
term effects of microcystin poisoning in sheep have been reported (Carbis
et al. 1995). A better understanding of post intoxication effects will depend upon longer–term toxicological studies and upon comprehensive epidemiological evidence, including longitudinal studies initiated after recognition of human and animal exposures.
Timely recognition of exposure events is needed. In global terms, human exposures to cyanobacterial toxins in drinking water supplies may occur sporadically as a consequence of treatment failures, deficiencies in
drinking water systems operations, or from the addition of copper sulfate
to reservoirs to terminate blooms of cyanobacteria. Epidemiological evidence is useful to describe the relationship between cyanobacterial toxin
exposure and human health outcomes. However, comprehensive information is difficult to collect due to the lack of knowledge of the risk of human
exposure to cyanobacterial toxins by water quality managers. When potentially toxic cyanobacterial blooms occur, they may be unrecognized as a
health threat and public health authorities may not be involved early in the
process. Therefore, the majority of outbreaks of human cyanobacterial
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toxicoses have been studied retrospectively and complete epidemiological
and environmental data has rarely been available.
A similar lack of knowledge may preclude identification of potential
adverse health effects associated with other potential routes of cyanobacterial toxin exposure such as recreational water activities, consumption of
contaminated fish, or dietary supplements contaminated by toxic cyanobacteria. Ideally, for health effects research, these risks would be recognized during the period of exposure to toxic cyanobacteria, and measures
taken to protect human health. This timely identification of exposure
would allow better collection of epidemiological evidence and consequently improve the analysis of associated health effects and recovery.
Although there are no known antidotes to treat poisonings associated
with cyanobacterial toxins, people and animals may be treated by various
supportive measures such as intravenous fluid and electrolyte replacement,
corticosteroid therapy, assisted ventilation, and maintenance of acid–base
balance. Methods to reduce absorption such as gastric lavage, activated
charcoal or cholestyramine may also be used.
Potentially, if hepatotoxin poisoning is recognized soon after exposure,
survival may be improved using recent advances in acute liver support
therapy. Therapeutic use of the bioartificial liver, the molecular adsorbents recirculating system, portal vein arterialisation and human hepatocyte
transplantation may supplement the standard treatment for fulminant liver
failure – liver transplantation (Park and Lee 2005; Hay 2004; Nguyen et al.
2005; van de Kerkhove et al. 2005; Nardo et al. 2005; Baccarani et al.
2005; Tissières et al. 2005).
Maintenance of tissue oxygenation by intermittent positive pressure
ventilation may benefit victims of neurotoxin poisoning. Some have investigated this technique for anatoxin–a poisoning, with mixed results
(Carmichael et al. 1975; Carmichael et al. 1977; Beasley et al. 1989; Valentine et al. 1991). Artificial ventilation in conjunction with the potassium
channel blocker 4–aminopyridine has shown promise in reversing experimental saxitoxin poisoning (Chang et al. 1996).
However, emergency interventions on human and animal victims of
cyanobacterial toxicosis can only make a limited contribution to the understanding of post–intoxication intervention, as typically little is known
about the total absorbed dose. There is a need for experimental work designed specifically to investigate the efficacy of various therapeutic approaches.
Although a large number of animal poisonings and animal toxicity tests
have been reported, few have measured the effects of chronic or sub–
chronic exposure (Falconer et al. 1988; Guzman and Solter 1992; Falconer
et al. 1994; Fawell et al. 1994; Ito et al. 1997; Humpage et al. 2000b; Fal-
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coner and Humpage 2001; Humpage and Falconer 2003). Therefore, the
long–term risk associated with chronic, low–level exposure is less well
understood. However, this type of exposure scenario may be the most
common among human populations. The relative lack of animal data
makes epidemiological studies difficult due to the lack of case definitions
and biologic methods to confirm evidence of chronic or subchronic exposure to low levels of cyanobacterial toxins (Kuiper–Goodman et al. 1999).
There is a great disparity of information among cyanobacterial toxins.
Microcystins are the group of toxins most frequently studied, and there is
more information to support the understanding of the intoxication and detoxification process. However, even in the case of microcystins, research
into long–term exposures is needed to investigate reproductive toxicity,
teratogenicity and carcinogenicity effects in mammals. For other cyanobacterial toxins, such as cylindrospermopsin and the neurotoxins, anatoxins and saxitoxins, there are large knowledge gaps related to chronic toxicity and to the intoxication and detoxification process.
Charge 6: What are the research needs after exposure/
intoxication has occurred?

Near Term Research Priorities

• Initiate regular monitoring of water bodies at risk for toxic cyanobacteria blooms to enable remediation and timely health effects studies.
• Implement toxicologic studies that encompass multiple health endpoints
at frequent time intervals to examine the relationship between initial
intoxication, health effects and recovery at multiple life stages.
• Conduct studies to investigate the effectiveness of therapeutic approaches.
• Monitor food and supplements at risk for contamination with cyanobacterial toxins to enable public health intervention and timely health
effects studies.
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Charge 7
Where are we in the development of predictive models?
Predicting human health outcomes associated with cyanobacterial toxins
requires linking exposure estimates with dose–response models. Estimates
of toxin occurrence may be potentially derived from the models of bloom
dynamics, toxin production, and the fate and transport of the toxins.
Mechanistic models have been developed that can simulate a variety of
bloom characteristics and they have been useful in determining the significance of a variety of environmental variables that influence bloom dynamics (Bonnet and Poulin 2002; Thébault and Rabouille 2003; Håkanson et
al. 2003; Robson and Hamilton 2004; Arhonditsis and Brett 2005; Prokopkin et al. 2006) but their predictive capacity remains limited. In contrast,
inductive models, such as those employing artificial neural networks, appear to have the capacity to predict significant aspects of bloom dynamics
(Recknagel et al. 1997; Maier et al. 1998; Jeong et al. 2003).
A key step in using predictive models of bloom dynamics to predict exposures will be consideration of toxin fate and transport within aquatic
ecosystems. This will help to determine the relative importance of different routes of human exposure to cyanobacterial toxins. For example, there
is a potential for oral, inhalational and dermal exposures during recreational water use. Microcosm studies may provide an efficient means to
develop and evaluate the models that integrate bloom dynamics, toxin production, fate and transport to estimate such multi–route exposures. Reliable models predicting exposure via drinking water may be more difficult
to link to bloom dynamics given the uncertainties regarding the fate of toxins in water processing and the potential for by–products resulting from the
interaction of disinfection agents with cyanobacterial toxins.
Mechanistic models of human health effects based on stepwise links
from exposure to effect require toxicokinetic and toxicodynamic information that is largely unavailable for the majority of cyanobacterial toxins.
Furthermore, dose–response information is only currently available for a
small number of toxins for limited types of effects, suitable for use in more
basic modeling efforts. Alternatively, more 'intelligent' inductive models
may be used to predict human health outcomes from mixtures of cyanobacterial toxins based on data derived from experimental studies that employ characterized bloom extracts rather than pure toxin. While such extracts more accurately represent individual real–world blooms, their
complex and unique characteristics may limit the inferences that can be
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made until large numbers of blooms are characterized and their effects assessed.
The development of predictive models may also benefit from a more extensive characterization of the influence of temporal aspects of exposure
on various types of health outcomes. Different health outcomes are likely
to predominate as a result of acute, subchronic, chronic and episodic exposures. Only minimal data are currently available that are suitable for discriminating the impact of these temporal aspects of exposure on the variety
of potential human health outcomes. Predictive models are needed that
may be used by risk managers during decisions related to the costs and
benefits of surface water use and exposure.
To the extent that future experimental studies implicate a wider variety
of health outcomes as being influenced by cyanobacterial toxin exposure,
models will need to be developed to address more comprehensive predictions that include a variety of health outcomes in the human population.
Evaluation of such predictions will require corresponding biomarkers of
effect suitable for use in human populations to evaluate the validity of
model predictions.
While the primary linkage between bloom occurrence and human health
effects is presumed to be exposure to cyanobacterial toxins, the effects of
cyanobacterial blooms on ecosystem services may also influence human
health. While several international efforts are modeling the impact of
cyanobacterial blooms on ecosystems, assessing the impact of ecosystem
services on human health is emerging as an important area of research. At
this time it is difficult to assess the significance of ecosystem services for
modeling the effect of cyanobacteria blooms on human health.
Charge 7: Where are we in the development of predictive
models?

Near-term Research Priorities

• Implement toxicology studies to determine dose–response relationships
using oral, inhalational and dermal exposure routes.
• Implement studies of cyanobacterial toxin fate and transport in
environmental media.
• Characterize the toxicokinetics/toxicodynamics of parent toxin and
metabolites.
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Long-term Research Priorities

• Develop linkages between predictive models of bloom dynamics to
dose–response models of human health and ecologic effects outcomes.
• Investigate how cyanobacterial blooms reduce ecosystem services, and
the resulting effects on human and animal health.

Conclusion
In summary, we have identified multiple health effects research needs associated with exposure to cyanobacteria and cyanobacterial toxins.
• Affordable toxin standards are needed. However, in the short term,
research may be conducted with characterized clonal cyanobacteria
cultures that can be shared among laboratories.
• Studies of the health effects of chronic, episodic, and low–dose
exposures by environmentally—relevant routes are needed. Carcinogenicity, neurodevelopmental, neurotoxicology, and immunotoxicology studies are of immediate importance.
• Experimental studies of laboratory animals and observational studies of
populations exposed to mixtures of cyanobacterial toxins are needed. A
goal is to develop risk assessments of populations exposed to natural
blooms and mixtures of cyanobacterial toxins.
• The public health consequences of exposure to cyanobacteria and
cyanobacterial toxins are poorly characterized. Biomarkers of exposure
and effect are needed to use in human studies. Case reports and
observational epidemiologic studies are needed.
• Host susceptibility is poorly defined and should be systematically
examined among individuals involved in outbreaks of toxicoses, and
during experimental and observational studies.
• Timely and accurate exposure assessment is critical to detecting and
understanding cyanobacterial toxin—associated health effects. Systematic toxin occurrence monitoring is needed in water and food at risk for
contamination with potentially toxic cyanobacteria.
• Critical data gaps remain before predictive modeling of cyanobacteria–
associated health effects in populations is possible. Information about
the environmental fate and transport of toxins, the effects of cyanobacteria blooms on ecosystem services and population dynamics, the
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toxicokinetics/toxicodynamics of parent compounds and metabolites,
and dose–response data are needed.
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